Literature DB >> 4584050

Virulence of six strains of Mycobacterium bovis (BCG) in mice.

N A Sher, S D Chaparas, J Pearson, M Chirigos.   

Abstract

The abilities of six strains of Mycobacterium bovis strain BCG to replicate in vivo and to cause spleen enlargement in the CDF(1) male mouse were compared. The strains were grown in synthetic medium and harvested soon after complete pellicles were produced on liquid medium. In addition, two freeze-dried commercially available preparations were tested. The comparisons were made on the basis of injecting equal numbers of colony-forming units. Strain differences were marked. The Brazil strain was most effective in stimulating spleen enlargement, and the Japan strain was the least effective. This correlated with the number of colony-forming units isolated from the spleen.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4584050      PMCID: PMC422920          DOI: 10.1128/iai.8.5.736-742.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  THE VIRULENCE OF VARIOUS STRAINS OF BCG DETERMINED ON THE GOLDEN HAMSTER.

Authors:  A JESPERSEN; M W BENTZON
Journal:  Acta Tuberc Pneumol Scand       Date:  1964

2.  [PROSPECTS OF BCG STANDARDIZATION].

Authors:  F M LEVY; G CONGE; C FILLASTRE; E ORSSAUD
Journal:  Rev Hyg Med Soc       Date:  1963 Jul-Aug

3.  A modified semi-solid medium and technique for determining viability of BCG.

Authors:  S R ROSENTHAL; A H KENNIEBREW; N RAISYS
Journal:  Acta Tuberc Pneumol Scand       Date:  1962

4.  [12 years of experimentation on infection of hamsters by BCG].

Authors:  P HAUDUROY; W ROSSET
Journal:  Ann Inst Pasteur (Paris)       Date:  1963-01

5.  Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness.

Authors:  R J DUBOS; C H PIERCE
Journal:  Am Rev Tuberc       Date:  1956-11

6.  Combined chemoimmunostimulation therapy against murine leukemia.

Authors:  J W Pearson; G R Pearson; W T Gibson; J C Chermann; M A Chirigos
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

7.  Immunotherapy of malignant disease.

Authors:  S H Nadler; G E Moore
Journal:  Arch Surg       Date:  1969-09

8.  Comparison of strains of BCG. I. Antigenic analysis and tuberculin reactivity.

Authors:  S D Chaparas; S R Hedrick
Journal:  Infect Immun       Date:  1973-05       Impact factor: 3.441

9.  Mechanisms in antimicrobial immunity.

Authors:  F M Collins
Journal:  J Reticuloendothel Soc       Date:  1971-07

10.  Multiplication and survival of tubercle bacilli in the organs of mice.

Authors:  C H PIERCE; R J DUBOS; W B SCHAEFER
Journal:  J Exp Med       Date:  1953-02-01       Impact factor: 14.307

View more
  16 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Control of the Bcg gene of early resistance in mice to infections with BCG substrains and atypical mycobacteria.

Authors:  M Denis; A Forget; M Pelletier; R Turcotte; E Skamene
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

3.  The effect of BCG-vaccination on vaccinia virus infections in mice.

Authors:  G T Werner
Journal:  Experientia       Date:  1979-11-15

Review 4.  Vaccines and cell-mediated immunity.

Authors:  F M Collins
Journal:  Bacteriol Rev       Date:  1974-12

5.  Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

6.  Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.

Authors:  N A Sher; S D Chaparas; L E Greenberg; S Bernard
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

7.  Analysis of the cell wall of five strains of Myocbacterium tuberculosis BCG and of an attenuated human strain, W 115.

Authors:  P H Phiet; J Wietzerbin; E Zissman; J F Petit; E Lederer
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

8.  Enhancement activity of anti-mycobacterial sera in experimental Mycobacterium bovis (BCG) infection in mice.

Authors:  A Forget; J C Benoit; R Turcotte; N Gusew-Chartrand
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

9.  Differentiation of known strains of BCG from isolates of mycobacterium bovis and Mycobacterium tuberculosis by using mycobacteriophage 33D.

Authors:  W D Jones
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

10.  Purification of a mycobacterial adhesin for fibronectin.

Authors:  T L Ratliff; R McCarthy; W B Telle; E J Brown
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.